Researchers at the University of North Carolina have developed a new immunotherapy approach that could transform treatment for acute myeloid leukemia (AML), a deadly blood cancer. The team, led by immunologist Gianpietro Dotti and hematologist Paul Armistead, has engineered immune cells capable of destroying AML cells while sparing healthy blood tissue, overcoming a major limitation of existing therapies that often fail to distinguish between cancerous and normal cells. Their findings, published in the journal Blood, represent a significant step forward in the fight against this disease.
AML is a fast-growing cancer that affects the blood and bone marrow, and current treatments, such as chemotherapy and stem cell transplants, can be highly toxic and often damage healthy cells along with cancerous ones. The new approach, which involves modifying T cells to recognize and attack AML-specific markers, could reduce side effects and improve patient outcomes. According to the study, the engineered cells showed potent activity against AML in preclinical models while leaving normal blood cells unharmed.
This research is part of a broader effort to develop more targeted and less toxic cancer therapies. The implications are significant: if successful in clinical trials, this therapy could provide a new option for patients who have limited treatment choices. The ability to spare healthy tissue could also reduce the risk of complications, such as infections and bleeding, that often accompany conventional treatments.
The importance of this work is underscored by the ongoing efforts of companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), which are also focused on advancing cancer therapies. However, the UNC team's approach specifically addresses a critical challenge in AML treatment: the difficulty of selectively targeting cancer cells without harming the blood system.
Experts note that while the results are promising, further research is needed to confirm the therapy's safety and efficacy in humans. The team is now working to optimize the engineered cells and prepare for clinical trials. If successful, this could lead to more advanced and even side-effect-free cancer therapies in the future.
For more information on this topic, visit TinyGems.com for additional coverage of innovative biotech developments. TinyGems is a communications platform that focuses on small-cap and mid-cap companies with growth potential.
